{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:40:13Z","timestamp":1784734813528,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH295"],"award-info":[{"award-number":["ZR2023MH295"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Hepatic sinusoidal obstruction syndrome (HSOS) is a rare but life-threatening liver condition. The clinical utility of transjugular intrahepatic portosystemic shunt (TIPS) for HSOS remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review and meta-analysis was performed across five databases (up to November 2024) to evaluate the efficacy and safety of TIPS in HSOS patients. Key outcomes included technical success, clinical response, portal pressure changes, survival, and complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen studies involving 465 patients were included. Pooled technical success and clinical response rates were 100 and 94.2%, respectively. TIPS significantly reduced portal pressure (mean PPG: \u221213.5 mmHg; PVP: \u221212.3 mmHg). The 3-month and 1-year survival rates were both 91.6%. Hepatic encephalopathy occurred in 13.2% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TIPS is a feasible and relatively safe treatment for HSOS, particularly in patients with pyrrolizidine alkaloid\u2013induced HSOS (PA-HSOS). Further research is warranted to confirm its long-term benefits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024620323<\/jats:uri>, identifier CRD42024620323.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1625825","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:32:51Z","timestamp":1755063171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of transjugular intrahepatic portosystemic shunt in hepatic sinusoidal obstruction syndrome: systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinghe","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European society for blood and marrow transplantation (EBMT).","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2006.02742.x","article-title":"Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome.","volume":"23","author":"Helmy","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation.","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.dld.2023.01.118","article-title":"Clinical impact and treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) after liver transplant (LT). The role of transjugular intrahepatic porto-systemic shunt (TIPS).","volume":"55","author":"Triolo","year":"2023","journal-title":"Digestive Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12876-018-0879-7","article-title":"Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.14612","article-title":"Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"34","author":"Zhuge","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/s0016-5085(03)00377-9","article-title":"Transjugular intrahepatic portosystemic shunt: current status.","volume":"124","author":"Boyer","year":"2003","journal-title":"Gastroenterology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/j.1440-1746.2005.03878.x","article-title":"Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt.","volume":"20","author":"Khuroo","year":"2005","journal-title":"J Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1080\/10428190410001663626","article-title":"Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.","volume":"45","author":"Annaloro","year":"2004","journal-title":"Leuk Lymphoma."},{"key":"B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data.","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.bbmt.2020.08.006","article-title":"Transjugular intrahepatic portosystemic shunt for very severe veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) after unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.","volume":"26","author":"G\u00f3mez-Centuri\u00f3n","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.3748\/wjg.v26.i24.3472","article-title":"Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.","volume":"26","author":"Zhou","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12876-021-01599-7","article-title":"Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/MEG.0000000000002591","article-title":"Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study.","volume":"35","author":"Huang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e23455","DOI":"10.1016\/j.heliyon.2023.e23455","article-title":"Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: a multicenter retrospective study.","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon."},{"key":"B17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00270-023-03451-9","article-title":"Transjugular intrahepatic portosystemic shunt benefits for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum: a propensity score-matched analysis.","volume":"46","author":"Li","year":"2023","journal-title":"Cardiovasc Intervent Radiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21743","DOI":"10.1038\/s41598-021-01201-w","article-title":"Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"11","author":"Wu","year":"2021","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/liv.13684","article-title":"Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.","volume":"38","author":"Zhuge","year":"2018","journal-title":"Liver Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MEG.0000000000002509","article-title":"Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"35","author":"Huang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/sj.bmt.1702386","article-title":"Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation.","volume":"25","author":"Azoulay","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep.510240321","article-title":"Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation.","volume":"24","author":"Fried","year":"1996","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3760\/cma.j.cn501113-20221012-00493","article-title":"Evaluation of the efficacy of TIPS in 27 patients with hepatic sinus obstruction syndrome in the near and medium term.","volume":"31","author":"Wang","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.11569\/wcjd.v23.i26.4261","article-title":"Efficacy of transjugular intrahepatic portosystemic stent-shunt in treatment of gynura segetum induced hepatic veno-occlusive disease with refractory ascites.","volume":"23","author":"Wang","year":"2015","journal-title":"World Chinese J Digestol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3760\/cma.j.issn.0254-1432.2019.04.006","article-title":"Efficacy of transjugular intrahepatic portosystemic shunt in the treatment of 21 patients with gynura segetum-related hepatic sinusoidal obstruction syndrome.","volume":"39","author":"Changlong","year":"2019","journal-title":"Chinese J Digestion."},{"key":"B26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3760\/cma.j.issn.1007-8118.2019.06.005","article-title":"Efficacy of transjugular intrahepatic portosystemic shunt in treatment of sinusoidal obstruction syndrome caused by gynura segetum.","volume":"25","author":"Wei","year":"2019","journal-title":"Chinese J Hepatobiliary Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3760\/cma.j.issn.0254-1432.2016.12.003","article-title":"Treatment for Gynura segetum caused hepatic vein occlusive disease: a single-center retrospective study.","volume":"36","author":"Yi","year":"2016","journal-title":"Chinese J Digestion."},{"key":"B28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12072-020-10126-x","article-title":"Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.","volume":"15","author":"Xiao","year":"2021","journal-title":"Hepatol Int."},{"key":"B29","first-page":"204A","article-title":"Tips might be effective for patients with acute hepatic veno-occlusive disease caused by pyrrolizidine alkaloids with no response to anticoagulation therapy: A single center retrospective study.","volume":"68","author":"Zhang","year":"2018","journal-title":"Hepatology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3760\/cma.j.cn113884-20220305-00088","article-title":"Clinical impact of transjugular intrahepatic portosystemic shunt on refractory hepatic sinus obstruction syndrome caused by Gynura segetum.","volume":"28","author":"Xu","year":"2022","journal-title":"Chinese J Hepatobiliary Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","article-title":"EASL Clinical Practice Guidelines on liver transplantation.","volume":"81","year":"2024","journal-title":"J Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1055\/s-0039-1698763","article-title":"Efficacy and safety of defibrotide for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis.","volume":"45","author":"Yang","year":"2019","journal-title":"Semin Thromb Hemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/ijh-2017-0015","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome with multiorgan failure.","volume":"6","author":"Richardson","year":"2017","journal-title":"Int J Hematol Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1034\/j.1600-0676.2001.210105.x","article-title":"Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation\u2013role of transjugular intrahepatic portosystemic shunt (TIPS).","volume":"21","author":"Zenz","year":"2001","journal-title":"Liver."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e000531","DOI":"10.1136\/bmjgast-2020-000531","article-title":"Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).","volume":"7","author":"de Wit","year":"2020","journal-title":"BMJ Open Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625825\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:32:56Z","timestamp":1755063176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625825\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":37,"alternative-id":["10.3389\/fmed.2025.1625825"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1625825","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1625825"}}